Timothy Braden
Pfizer
9 Papers
393 Citations
Timothy Braden is an academic researcher from Pfizer. The author has contributed to research in topics: Luciferase & Protein engineering. The author has an hindex of 7, co-authored 9 publications. Previous affiliations of Timothy Braden include Parke-Davis.
Chat about Author
Papers
Metabonomics: Evaluation of Nuclear Magnetic Resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants
Donald G. Robertson,Michael D. Reily,Robert E. Sigler,Dale F. Wells,David Paterson,Timothy Braden +5 more
TL;DR: The results demonstrated that the metabonomic approach could readily distinguish the onset and reversal of toxicity with good agreement between clinical chemistry and PCA data, and support the contention that the metabolism approach represents a promising new technology for the development of a rapid throughput in vivo toxicity screen.
268
The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation.
Xiao Hu,Sarah Du,Cansu Tunca,Timothy Braden,Kelly R. Long,Jamie Lee,Elizabeth G. Webb,Jessica D. Dietz,Susan Hummert,Sharon Rouw,Shridhar Hegde,R. Keith Webber,Mark Gerard Obukowicz +12 more
TL;DR: Results suggest that these ligands are promising candidates with robust antiinflammatory activity and likely dissociation against glucocorticoid-induced side effects.
Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors
Mark S. Plummer,Joseph A. Cornicelli,Howard Roark,Skalitzky Donald James,Charles J. Stankovic,Susan E. Bove,Jayvardhan Pandit,Annise Paige Goodman,James Hicks,Aurash B Shahripour,David Beidler,Xiao Kang Lu,Brian Sanchez,Christopher Whitehead,Ron Sarver,Timothy Braden,Richard Gowan,Xi Qiang Shen,Katherine Welch,Adam Ogden,Nalini Sadagopan,Heidi Baum,Howard Miller,Craig Banotai,Cindy Spessard,Sandra Lightle +25 more
TL;DR: These newly designed PDE2 inhibitors bind to the PDE 2 enzyme in a cGMP-like mode in contrast to the cAMP-like binding mode found in PDE4, identified by optimizing residual PDE1 activity in a series of Pde4 inhibitors, while simultaneously minimizing PDE 4 activity.
23
Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: Optimization studies and demonstration of in vivo efficacy
Mark S. Plummer,Joseph A. Cornicelli,Howard Roark,Skalitzky Donald James,Charles J. Stankovic,Susan E. Bove,Jayvardhan Pandit,Annise Paige Goodman,James Hicks,Aurash B Shahripour,David Beidler,Xiao Kang Lu,Brian Sanchez,Christopher Whitehead,Ron Sarver,Timothy Braden,Richard Gowan,Xi Qiang Shen,Katherine Welch,Adam Ogden,Nalini Sadagopan,Heidi Baum,Howard Miller,Craig Banotai,Cindy Spessard,Sandra Lightle +25 more
TL;DR: PDE2 inhibitors identified by optimizing residual PDE2 activity in a series of phosphodiesterase 4 (PDE4) inhibitors, while minimizing PDE4 inhibitory activity have efficacy in a rat model of osteoarthritis (OA) pain.
20
Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase.
Justin I. Montgomery,Peter L. Toogood,Kim Hutchings,Jia Liu,Lakshmi Narasimhan,Timothy Braden,Michael R. Dermyer,Angela D. Kulynych,Smith Yvonne Dorothy,Joseph S. Warmus,Clarke Taylor +10 more
TL;DR: A series of benzyl phenyl ethers (BPEs) is described that displays potent inhibition of bacterial phenylalanyl-tRNA synthetase.
20